Chemotherapy Combined With Endocrine Therapy: Old Wine in a New Bottle?

IF 2.9 3区 医学 Q2 ONCOLOGY Clinical breast cancer Pub Date : 2024-08-24 DOI:10.1016/j.clbc.2024.08.018
Nengying Zhang , Liyi Pan , Tao Weng , Jiayang Li , Yuxiang Bao , Zhongliang Yan , Taolang Li , Xiaoming Cheng , Junyuan Lv
{"title":"Chemotherapy Combined With Endocrine Therapy: Old Wine in a New Bottle?","authors":"Nengying Zhang ,&nbsp;Liyi Pan ,&nbsp;Tao Weng ,&nbsp;Jiayang Li ,&nbsp;Yuxiang Bao ,&nbsp;Zhongliang Yan ,&nbsp;Taolang Li ,&nbsp;Xiaoming Cheng ,&nbsp;Junyuan Lv","doi":"10.1016/j.clbc.2024.08.018","DOIUrl":null,"url":null,"abstract":"<div><div>Both chemotherapy (CT) and endocrine therapy (ET) play important roles in the systemic treatment of breast cancer (BC). However, previous studies have shown an antagonistic effect when CT and ET are administered simultaneously. Therefore, sequential administration is more effective than combined administration. The current guidelines and consensus recommend a sequential schedule of CT and ET for patients with hormone receptor-positive (HR+) BC. However, with the continuous introduction of new endocrine drugs, the question of whether the simultaneous administration of CT and ET is superior to sequential therapy has surfaced again as a hot topic of clinical concern. Recent studies have shown that the combination of certain chemotherapeutic agents with endocrine drugs has a synergistic effect. This review aims to summarize the new advances achieved in recent years on the old topic of CT combined with ET in the treatment of BC.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"24 8","pages":"Pages e737-e747"},"PeriodicalIF":2.9000,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1526820924002295","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Both chemotherapy (CT) and endocrine therapy (ET) play important roles in the systemic treatment of breast cancer (BC). However, previous studies have shown an antagonistic effect when CT and ET are administered simultaneously. Therefore, sequential administration is more effective than combined administration. The current guidelines and consensus recommend a sequential schedule of CT and ET for patients with hormone receptor-positive (HR+) BC. However, with the continuous introduction of new endocrine drugs, the question of whether the simultaneous administration of CT and ET is superior to sequential therapy has surfaced again as a hot topic of clinical concern. Recent studies have shown that the combination of certain chemotherapeutic agents with endocrine drugs has a synergistic effect. This review aims to summarize the new advances achieved in recent years on the old topic of CT combined with ET in the treatment of BC.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
化疗联合内分泌治疗:新瓶装旧酒?
化疗(CT)和内分泌治疗(ET)在乳腺癌(BC)的全身治疗中都发挥着重要作用。然而,以往的研究表明,同时使用 CT 和 ET 会产生拮抗作用。因此,序贯用药比联合用药更有效。目前的指南和共识建议对激素受体阳性(HR+)的乳腺癌患者按顺序使用 CT 和 ET。然而,随着新型内分泌药物的不断推出,CT 和 ET 同时使用是否优于序贯治疗的问题再次浮出水面,成为临床关注的热点话题。最新研究表明,某些化疗药物与内分泌药物联合使用具有协同作用。本综述旨在总结近年来在 CT 联合 ET 治疗 BC 这一老话题上取得的新进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical breast cancer
Clinical breast cancer 医学-肿瘤学
CiteScore
5.40
自引率
3.20%
发文量
174
审稿时长
48 days
期刊介绍: Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.
期刊最新文献
Editorial Board Table of Contents Clinical and Imaging Features Associated With Malignant Focal Nonmass Enhancement on Breast MRI. Real-World Outcomes of Pyrotinib-Based Therapy for HER2-Positive Breast Cancer With Brain Metastases: A Multicentre, Retrospective Analysis. Another Biosignature for Ductal Carcinoma In Situ-Have We Moved the Needle?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1